<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459640</url>
  </required_header>
  <id_info>
    <org_study_id>FF-114-2011</org_study_id>
    <nct_id>NCT01459640</nct_id>
  </id_info>
  <brief_title>Intra-Articular Autologous Bone Marrow Mesenchymal Stem Cells Transplantation to Treat Mild to Moderate Osteoarthritis</brief_title>
  <official_title>Phase 2 Study Assessing the Efficacy of Intra-Articular Autologous Mesenchymal Stem Cells in Patients With Mild to Moderate Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University of Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cytopeutics Pte. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National University of Malaysia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoarthritis is a progressively degenerative disease resulting in increasing pain,
      impairment and ultimately disability. While the available treatments seek to ameliorate pain
      or improve mobility, these treatments rarely modify the course of the disease, but rather
      attend to its consequences. For early stage osteoarthritis, treatment is largely limited to
      addressing the symptoms of inflammation with non-steroidal anti-inflammatory drugs (NSAIDs).
      These drugs do not stop the progression of the condition or regenerates damaged cartilage.

      This is a randomized and open labelled study aimed to determine the efficacy of
      intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in
      patients with mild to moderate osteoarthritis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in cartilage thickness at 12 months by MRI</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>1 month, 3 months, 6 months, 9 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IKDC Subjective Knee Evaluation Form (2000)</measure>
    <time_frame>1 month, 3 months, 6 months, 9 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in progression of osteoarthritis at 12 months by plain radiograph (X-ray)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Hyaluronic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bone marrow mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous bone marrow-derived mesenchymal stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic Acid</intervention_name>
    <description>Intra-articular injection; 30mg/2ml; three-weekly injection regimen</description>
    <arm_group_label>Hyaluronic acid</arm_group_label>
    <other_name>Orthovisc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous bone marrow-derived mesenchymal stem cells</intervention_name>
    <description>Single intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in hyaluronic acid &quot;Orthovisc&quot; (3rd injection in a three-weekly injection regimen)</description>
    <arm_group_label>Bone marrow mesenchymal stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with mild to moderate osteoarthritis based on Kellgren-Lawrence radiographic
             classification

          -  Has a history of joint swelling, pain, stiffness, altered gait and loss of motion due
             to degenerative cartilage

        Exclusion Criteria:

          -  Has systemic bone or cartilage disorders

          -  Has significant vascular impairment proximal to implant site

          -  Has substantial joint destabilization including extensive osteophyte formation

          -  Has substantial surface erosion of the weight-bearing articular cartilage

          -  Evidence of infection or fractures in or around the joint

          -  Contraindication to bone marrow aspiration

          -  Any acute or chronic communicable diseases including Hepatitis B, Hepatitis C and HIV

          -  Any past history of neoplasia and primary hematological disease

          -  Renal impairment indicated by serum creatinine greater than 200mM

          -  Liver impairment indicated by serum aspartate transaminase and serum alanine
             transaminase greater than 120 IU

          -  Any other co-morbidity which the physician deems as a contraindication to stem cell
             transplantation and bone marrow biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ya Mohammad Hassan Shukur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UKM Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ya Mohammad Hassan Shukur, MD</last_name>
    <email>mhassan@ppukm.ukm.my</email>
  </overall_contact>
  <location>
    <facility>
      <name>UKM Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ya Mohammad Hassan Shukur, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ya Mohammad Hassan Shukur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johan Ahmad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2011</study_first_submitted>
  <study_first_submitted_qc>October 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2011</study_first_posted>
  <last_update_submitted>October 24, 2011</last_update_submitted>
  <last_update_submitted_qc>October 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University of Malaysia</investigator_affiliation>
    <investigator_full_name>Dr Ya Mohammad Hassan Shukur</investigator_full_name>
    <investigator_title>Senior Consultant Orthopedic Surgeon</investigator_title>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>Autologous</keyword>
  <keyword>Mild osteoarthritis</keyword>
  <keyword>Moderate osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

